医学信息
醫學信息
의학신식
MEDICAL INFORMATION
2013年
26期
141-142
,共2页
胡信军%高珊%方臻飞%胡信群
鬍信軍%高珊%方臻飛%鬍信群
호신군%고산%방진비%호신군
硝苯地平%氨氯地平%高血压%疗效
硝苯地平%氨氯地平%高血壓%療效
초분지평%안록지평%고혈압%료효
Nifedipine%Amlodipine%High blood pressure%The curative ef ect
目的:探讨硝苯地平与氨氯地平治疗高血压的临床疗效和安全性。方法选取我院2010年1月~2012年1月收治的高血压患者80例进行研究,按照随机分组原则划分为观察组和对照组各40例,观察组患者采用氨氯地平进行治疗,对照组采用硝苯地平进行治疗,对两组治疗临床效果及安全性进行观察和对比分析。结果观察组和对照组治疗后高血压指标均较治疗前显著改善(P<0.05),且观察组治疗有效率优于对照组,对比差异显著(P<0.05),两组不良反应均较少。结论硝苯地平和氨氯地平治疗高血压,均具有较为有效的临床疗效,但氨氯地平的治疗效果优于硝苯地平,不良反应少,值得临床应用推广。
目的:探討硝苯地平與氨氯地平治療高血壓的臨床療效和安全性。方法選取我院2010年1月~2012年1月收治的高血壓患者80例進行研究,按照隨機分組原則劃分為觀察組和對照組各40例,觀察組患者採用氨氯地平進行治療,對照組採用硝苯地平進行治療,對兩組治療臨床效果及安全性進行觀察和對比分析。結果觀察組和對照組治療後高血壓指標均較治療前顯著改善(P<0.05),且觀察組治療有效率優于對照組,對比差異顯著(P<0.05),兩組不良反應均較少。結論硝苯地平和氨氯地平治療高血壓,均具有較為有效的臨床療效,但氨氯地平的治療效果優于硝苯地平,不良反應少,值得臨床應用推廣。
목적:탐토초분지평여안록지평치료고혈압적림상료효화안전성。방법선취아원2010년1월~2012년1월수치적고혈압환자80례진행연구,안조수궤분조원칙화분위관찰조화대조조각40례,관찰조환자채용안록지평진행치료,대조조채용초분지평진행치료,대량조치료림상효과급안전성진행관찰화대비분석。결과관찰조화대조조치료후고혈압지표균교치료전현저개선(P<0.05),차관찰조치료유효솔우우대조조,대비차이현저(P<0.05),량조불량반응균교소。결론초분지평화안록지평치료고혈압,균구유교위유효적림상료효,단안록지평적치료효과우우초분지평,불량반응소,치득림상응용추엄。
Objective:to study the nifedipine and amlodipine clinical ef icacy and safety for the treatment of high blood pressure. Methods: from January 2010 to January 2012 between the treated 80 cases of patients with high blood pressure, in accordance with the principle of randomized divided into observation group and control group 40 cases, observation group were treated by amlodipine treatment, control group treated with nifedipine, clinical ef ect and safety of two groups of treatment for observation and comparative analysis. Results:the observation group and control group after treatment of high blood pressure index than before treatment significantly improved (P<0.05), and ef icient observation treatment group is bet er than that of control group, compared with significant dif erence (P< 0.05), two groups of adverse reactions are less. Conclusions: nifedipine and amlodipine treatment of high blood pressure, have more ef ective clinical curative ef ect, but the therapeutic ef ect of amlodipine is bet er than nifedipine, less adverse reactions, worthy of clinical promotion.